Diabetes Technology & Therapeutics

Papers
(The H4-Index of Diabetes Technology & Therapeutics is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Impact of Sample Type on ADAP-Based Autoantibody Detection for Type 1 Diabetes Population Screening185
New Insulins, Biosimilars, and Insulin Therapy182
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes136
Statistically Adjusting for Wear Time in Randomized Trials of Continuous Glucose Monitors as a Complement to Intent-to-Treat and As-Treated Analyses: Application and Evaluation in Two Trials129
Comparison of Cgmanalysis, a Free Open-Source Continuous Glucose Monitoring Data Management and Analysis Software, with Commercially Available CGM Platforms: Data Standardization for Diabetes Technolo87
Glycemia Around Exercise in Adults with Type 1 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A Switch Pilot Trial82
Clinical Evaluation of a Novel CGM-Informed Bolus Calculator with Automatic Glucose Trend Adjustment69
The Effect of Control IQ Hybrid Closed Loop Technology on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes62
Is It Time to Replace Time-in-Range with Time-in-Tight-Range? Maybe Not60
Safety and Functionality of a Novel Clinical Decision-Support Algorithm with Insulin Efsitora Alfa in Adults with Type 2 Diabetes: Early Feasibility Study58
The Official Journal of ATTD Advanced Techologies & Treatments for Diabetes CONFERENCE 6–9 MARCH 2024 I FLORENCE & ONLINE57
Real-Life Achievements of MiniMed 780G Advanced Closed-Loop System in Youth with Type 1 Diabetes: AWeSoMe Study Group Multicenter Prospective Trial57
Letter: Response to: “Lack of Association Between Hemoglobin A1c and Continuous Glucose Monitor Metrics Among Individuals with Prediabetes and Normoglycemia”56
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies55
Disordered Eating Behaviors Among Adolescents and Young Adults with Type 1 Diabetes Treated with Insulin Pumps and Hybrid Closed-Loop Systems54
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes53
A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor51
Letter: Tirzepatide in Type 1 Diabetic Obese Patient Using Hybrid Closed-Loop51
Practical Considerations and Implementation of Automated Insulin Delivery Systems50
Metabolic Models, in Silico Trials, and Algorithms49
A Call-to-Action to Eliminate Barriers to Accessing Automated Insulin Delivery Systems for People with Type 1 Diabetes48
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin47
Early Real-World Performance of the MiniMed™ 780G Advanced Hybrid Closed-Loop System and Recommended Settings Use in the United States47
Acknowledgment of Reviewers: 202446
A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes45
Relationship Between Moderate-to-Vigorous Physical Activity and Glycemia Among Young Adults with Type 1 Diabetes and Overweight or Obesity: Results from the Advancing Care for Type 1 Diabetes and Obes45
A Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2 h After a Meal in Adults with Type 1 Diabetes Treated with an Automated Insulin Delivery System45
Software Packages and Tools for the Analysis of Continuous Glucose Monitoring Data43
Continuous and Intermittent Glucose Monitoring in 202143
Insulin Delivery Hardware: Pumps and Pens41
WITHDRAWN: Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial39
Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes38
Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes37
Decision Support Tool for Self-Management of Insulin Dosing in Type 1 Diabetes with Multiple Daily Injections: A Proof-of-Concept Study37
A Retrospective Real-Life Study to Compare Glycemic Control Between Simplified Meal Size Estimation and Precise Carbohydrates Counting in Type 1 Diabetes Patients Using DBLG1 Hybrid Closed-Loop System36
The Future of Dual Glucose–Ketone Monitoring in Youth with Diabetes36
0.20600199699402